Table 2.

Sorafenib administration in the safety population (N = 331)

Duration of treatment
Missing	12 (3.6)
≤ 4 weeks	21 (6.3)
> 4 and ≤8 weeks	37 (11)
> 8 and ≤12 weeks	51 (15)
> 12 and ≤16 weeks	23 (6.9)
> 16 and ≤20 weeks	17 (5.1)
> 20 and ≤24 weeks	19 (5.7)
> 24 and ≤28 weeks	15 (4.5)
> 28 weeks	136 (41)
Treatment duration (weeks) for available patients
Number	319
Mean ± SD	29.54 ± 24.79
Median (range)	22.30 (0.1 to 116.1)
Average daily dose (mg)
Number	204
Mean ± S D	776.2 ± 83.6
Median (range)	800 (332 to 818)
Total dose (mg)
Number	204
Mean ± SD	133,512.3 ± 115,060.0
Median (range)	198,350 (800 to 600,800)
Dose intensity (%)
Number	204
Mean ± SD	96.5 ± 11.8
Median (range)	100 (26 to 102)
Actual days on study drug (excluding off days)
Number	204
Mean ± SD	171.4 ± 146.3
Median (range)	127.5 (1 to 751)
Initial sorafenib dose level
Number	331
400 mg	4 (1.2)
600 mg	1 (0.3)
800 mg	326 (98)
Total subjects with dose interruptions ticked, yes	7 (2.1)
Total subjects with dose modification ticked, yes	27 (8.2)
Total subjects with dose increase, yes	13 (3.9)
Total subjects with dose reduction, yes	21 (6.3)

Data are presented as mean ± standard deviation, median (range) or count (percentage). Percentages are presented to 2 significant figures